Clodronate disodium is neither cytotoxic nor cytoprotective to normal and recombinant equine interleukin-1β-treated joint tissues in vitro.
Journal
Veterinary surgery : VS
ISSN: 1532-950X
Titre abrégé: Vet Surg
Pays: United States
ID NLM: 8113214
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
25
06
2022
received:
19
04
2022
accepted:
30
08
2022
pubmed:
12
10
2022
medline:
31
12
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
To determine the effects of clodronate disodium (CLO) on control and recombinant equine interleukin-1β (IL-1β)-treated equine joint tissues. In vitro experimental study. Cartilage explants, chondrocytes, and synoviocytes (n = 3 horses). Monolayer cultures of chondrocytes and synoviocytes from three horses were subjected to: control media (CON), 5 ng/ml CLO (C/low), 50 ng/ml CLO (C/med), 100 ng/ml CLO (C/high), with and without IL-1β, and 10 ng/ml IL-1β (IL) alone for 72 hours. Cartilage explants from three horses were subjected to CON, IL, C/low, and C/med with and without IL-1β for 72 hours. Culture media was analyzed for prostaglandin-E IL-1β treatment resulted in higher media concentrations of GAG, NO, PGE CLO did not demonstrate cytotoxic nor cytoprotective effects in normal and IL-1β-stimulated chondrocytes, synoviocytes or explants in culture. This study does not support the use of CLO as an anti-inflammatory treatment. Further research is necessary to confirm any anti-inflammatory effects of CLO on joint tissues.
Substances chimiques
Interleukin-1beta
0
Clodronic Acid
0813BZ6866
Interleukin-6
0
Glycosaminoglycans
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146-156Subventions
Organisme : American College of Veterinary Surgeons Foundation
Informations de copyright
© 2022 American College of Veterinary Surgeons.
Références
Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19.
Mitchell A, Watts AE, Ebetino FH, Suva LJ. Bisphosphonate use in the horse: what is good and what is not? BMC Vet Res. 2019;15(1):1-7. doi:10.1186/S12917-019-1966-X
Anastasilakis AD, Polyzos SA, Makras P. Review Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179(1):31-45.
Baykan EK, Saygili LF, Erdogan M, Cetinkalp S, Ozgen AG, Yilmaz C. Efficacy of zoledronic acid treatment in Paget disease of bone. Osteoporos Int. 2014;25(9):2221-2223.
D'Eufemia P, Finocchiaro R, Celli M, et al. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment. Pediatr Res. 2008;63(2):203-206.
U.S. Food and Drug Administration. Animal Drugs @ FDA. Accessed June 20, 2022. https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141-420
Maksymowych WP. Bisphosphonates-anti-inflammatory properties. Antiinflamm Antiallergy Agents Med Chem. 2002;1:15-28.
Garganta MD, Jaser SS, Lazow MA, et al. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta. BMC Musculoskelet Disord. 2018;19(1):344. doi:10.1186/s12891-018-2252-y
Mitchell A, Wright G, Sampson SN, et al. Clodronate improves lameness in horses without changing bone turnover markers. Equine Vet J. 2019;51(3):356-363.
Duesterdieck-Zellmer KF, Moneta L, Ott JF, et al. Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β. Am J Vet Res. 2012;73(10):1530-1539.
Mönkkönen J, Pennanen N, Lapinjoki S, Urtti A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci. 1994;54(14):PL229-PL234.
Denoix JM, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet J. 2003;35(4):407-413.
Coudry V, Thibaud D, Riccio B, Audigié F, Didierlaurent D, Denoix JM. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. Am J Vet Res. 2007;68(3):329-337.
Gough MR, Thibaud D, Smith RKW. Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial. Equine Vet J. 2010;42(5):381-387.
Bertuglia A, Basano I, Pagliara E, Bottegaro NB, Spinella G, Bullone M. Effect of intravenous tiludronate disodium administration on the radiographic progression of osteoarthritis of the fetlock joint in Standardbred racehorses. J Am Vet Med Assoc. 2021;259(6):651-661.
Krueger CR, Mitchell CF, Leise BS, Knych HK. Pharmacokinetics and pharmacodynamics of clodronate disodium evaluated in plasma, synovial fluid and urine. Equine Vet J. 2020;52(5):725-732.
Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De LS. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis. 2002;61:925-928.
Barrera P, Blom A, Van Lent PL, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000;43(9):1951-1959.
Polfliet MM, Goede PH, van Kesteren-Hendrikx EM, van Rooijen N, Dijkstra CD, van den Berg TK. A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. J Neuroimmunol. 2001;116(2):188-195.
McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res. 2012;1(11):297-309.
Hussein MR, Fathi NA, Ezz El-Din AM, et al. Alterations of the CD4+, CD8+ T cell subsets, interleukins-1β, IL-10, IL-17, tumor necrosis factor-α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res. 2008;14:321-328.
Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252-270.
Takafuji VA, McIlwraith CW, Howard RD. Effects of equine recombinant interleukin-1α and interleukin-1β on proteoglycan metabolism and prostaglandin E2 synthesis in equine articular cartilage explants. Am J Vet Res. 2002;63(4):551-558.
Dechant JE, Baxter GM, Frisbie DD, Trotter GW, McIlwraith CW. Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Equine Vet J. 2003;35(5):444-450.
Fenton JI, Chlebek-Brown KA, Caron JP, Orth MW. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J. 2002;34(S34):219-223.
Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol. 2013;190:1297-1303.
Dombrecht EJ, Schuerwegh AJ, Bridts CH, et al. Effect of bisphosphonates on nitric oxide production by inflammatory activated chondrocytes. Clin Exp Rheumatol. 2007;25(6):817-822.
Van Offel JF, Dombrecht EJ, Bridts CH, et al. Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. Cytokine. 2005;31(4):298-304.
Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol. 1995;146(1):75-85.
Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018;6:469-472.
Chandrasekhar S, Esterman MA, Hoffman HA. Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal Biochem. 1987;161(1):103-108.
Soto SA, Barbará AC. Bisphosphonates: pharmacology and clinical approach to their use in equine osteoarticular diseases. J Equine Vet Sci. 2014;34(6):727-737.
van Weeren PR, de Grauw JC. Pain in osteoarthritis. Vet Clin North Am Equine Pract. 2010;26(3):619-642.
Chen Y, Jiang W, Yong H, et al. Macrophages in osteoarthritis: pathophysiology and therapeutics. Am J Transl Res. 2020;12(1):261-268.
Ewers BJ, Dvoracek-Driksna D, Orth MW, Haut RC. The extent of matrix damage and chondrocyte death in mechanically traumatized articular cartilage explants depends on rate of loading. J Orthop Res. 2001;19(5):779-784.
Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthr Cartil. 2000;8(4):258-265.
Makkonen N, Hirvonen MR, Teräväinen T, Savolainen K, Mönkkönen J. Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther. 1996;277(2):1097-1102.
Moriyama Y, Nomura M. Clodronate: a vesicular ATP release blocker. Trends Pharmacol Sci. 2018;39(1):13-23.
Zellmer S, Schmidt-Heck W, Godoy P, et al. Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. Hepatology. 2010;52(6):2127-2136.